A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 78, Issue 2, Pages 274-281
Publisher
Wiley
Online
2014-01-17
DOI
10.1111/bcp.12318
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma
- (2012) Tung-Liang Lin et al. ANNALS OF HEMATOLOGY
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- (2012) C. Muller et al. BLOOD
- Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
- (2012) P.-C. Tsai et al. CLINICAL CANCER RESEARCH
- Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
- (2012) U. Jager et al. HAEMATOLOGICA
- Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
- (2012) S. Angelini et al. HAEMATOLOGICA
- Target Concentration Intervention in Oncology
- (2012) Mohamed Saleem et al. THERAPEUTIC DRUG MONITORING
- Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma
- (2011) David Ternant et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- HomozygousFCGR3A-158Valleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma
- (2011) C. Keane et al. INTERNAL MEDICINE JOURNAL
- Chronic Myeloid Leukemia 2010: Where Are We Now and Where Can We Go?
- (2011) J. P. Radich Hematology-American Society of Hematology Education Program
- Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism
- (2010) Szu-Chin Li et al. AMERICAN JOURNAL OF HEMATOLOGY
- Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study
- (2010) Yuichi Ishikawa et al. CANCER SCIENCE
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia
- (2010) Ling-Na Ni et al. MEDICAL ONCOLOGY
- Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood
- (2009) Kenneth K. Khamly et al. INTERNATIONAL JOURNAL OF CANCER
- Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
- (2009) Liat Vidal et al. JNCI-Journal of the National Cancer Institute
- Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
- (2008) S. Dulucq et al. BLOOD
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
- (2008) D. Dayde et al. BLOOD
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Interaction of Imatinib with Human Organic Ion Carriers
- (2008) S. Hu et al. CLINICAL CANCER RESEARCH
- Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now